Phase I, Dose-escalation Trial of BAY1187982 in Subjects With Advanced Solid Tumors Known to Express Fibroblast Growth Factor Receptor 2 (FGFR2)

NCT02368951 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
20
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Bayer